EraGen signs Canadian Market Distribution Agreement for nucleic acid dection products

MADISON - EraGen Biosciences, announced today they have signed a distribution agreement with Inter Medico, Canada's leading independent distributor of advanced clinical in-vitro diagnostic products. The announcement follows the company’s distribution agreement announced last Wednesday with Promega.

"Both companies share the same goal; to create innovative solutions that provide strong long-term customer value. Inter Medico's highly skilled team provides specialized diagnostic products, services and support to many of Canada's leading hospitals, clinical reference laboratories, government, and biopharmaceutical laboratories,” said Irene Hruvosky, MD, president and CEO of EraGen.

"Exclusive strategic alliances with world-class manufacturers have allowed us to consistently deliver products that advance medicine and patient care. This exclusive Canadian strategic alliance with EraGen will allow us to expand our molecular diagnostic products to include state of the art diagnostic assay systems that shows significant improvement over traditional methods, as proven with their new SARS assays," said Dan Lichtman, President and CEO of Inter Medico.